二甲双胍及胰岛素增敏剂罗格列酮对非酒精性脂肪肝的效果观察

Metformin and insulin sensitizerrosiglitazone combination in improving nonalcoholic fatty liver disease

目的研究二甲双胍及胰岛素增敏剂罗格列酮对非酒精性脂肪性肝病(NAFLD)的疗效。方法选择我院门诊2009年1月至2012年1月收治的84例非酒精性脂肪性肝病患者,分为治疗组42例,对照组42例。治疗组采用二甲双胍联合胰岛素增敏剂罗格列酮进行治疗,对照组仅采用二甲双胍治疗,治疗6个月后对两组进行对比,期间均不服用其他保肝降酶药物。结果治疗组NAFLD的影像、血清生化相关指标变化比较均明显优于对照组,差异性具有统计学意义(P<0.05)。结论采用二甲双胍及胰岛素增敏剂罗格列酮治疗NAFLD临床治疗提升明显,用药安全。

Objective to study the combined use of metformin and insulin sensitizer rosiglitazone to improve nonalcoholic fatty liver disease（NAFLD）. Method Eight-two cases of NAFLD were slected from Jan 2009 to Jan 2012,including 42 cases with combined metformin and rosiglitazone treatmentgroup, and 42 cases with metformin only group. The therapeutic effects were evaluated 6 months after treatments without other hepatoprotective means Results Based on NAFLD images and the serum biochemical related indicators, The combined treatment of metformin and rosiglitation was significantly better than metformin alone（P〈0.05）. Conclusion metformin and insulin sensitizer rosiglitazone in the treatment of NAFLD could have better clinical outcomes with safety.